

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many she ets as necessary)

Sheet 1 of 5

	Complete if Known					
Application Number	10/591,923-Conf. #5393					
Filing Date	September 5, 2006					
First Named Inventor	Daniel J. Rader					
Art Unil	1614					
Examiner Name	Not Yet Assigned					
Attorney Dockel Number	AGP-002					

			<u>U.S. PA</u>	TENT DOCUMENTS	
Examiner	Cite	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan
nitials* /// 184_/	No.1	Number-Kind Code ² (if known)		Applicant of Gred Document	Figures Appear
<u>/K.W./</u>	A1*	US-20020035064-A1	03-21-2002	Robl et al.	
	A2*	US-20020045271-A1		Hussain et al.	
9990	A3*	US-20030069221-A1		Kosoglou et al.	
0000	A4*	US-20030109543-A1	06-12-2003	Ogletree	
000	A5*	US-20030162788-A1	08-28-2003	Thomas et al.	
0000	A6*	US-20030187053-A1	04-13-2004	Bertinato et al.	
	A7*		01-22-2004		
	A8*		03-25-2004		
20000	A9*	US-20050075367-A1	04-07-2005		
0000	A10*	US-20050090426-A1	04-28-2005	Blumberg	
90900	A11*	US-20050101561-A1	05-12-2005	Tunac	
0000	A12*	US-20060069161-A1	03-30-2006		
0000	A13*	US-20060135460-A1		Widder et al.	
00	A14*	US-20060153913-A1	07-13-2006	Yamane et al.	
	A15*			Hagiwara et al.	
	A16*	US-20060211020-A1	09-21-2006	Farrer et al.	
	A17*	US-20060211762-A1	09-21-2006	Rongen et al.	
0000	A18*	US-20060270655-A1	11-30-2006	Swick et al.	
9	A19*	US-20070088089-A1	04-19-2007	Wisler	
000	A20*	US-20070093468-A1	04-26-2007	Wisler	
0000	A21*	US-20070093527-A1	04-26-2007	Wisler	
	A22*	US-3,983,140	09-28-1976	Endo et al.	
0000		US-4,231,938	11-04-1980	Monaghan et al.	-
		US-4,346,227	08-24-1982	Terahara et al.	
		US-4,448,784	05-15-1984	Glamkowski et al.	
0000		US-4,450,171	05-22-1984	Hoffman et al.	
000		US-4,499,289	02-12-1985	Baran et al.	
000		US-4,613,610	09-23-1986	Wareing	
000		US-4,647,576	03-03-1987	Hoefle et al.	
8		US-4,686,237	08-11-1987	Anderson	
		US-4,871,721	10-03-1989	Biller	
***************************************		US-4,924,024	05-08-1990	Biller	
-		US-5,117,080	05-26-1992	Lee et al.	
***************************************		US-5,595,872	01-21-1997	Wetterau, II et al.	
8		US-5,684,014	11-04-1997	Muller et al.	
8		US-5,712,279	01-27-1998		
00000		US-5,712,396	01-27-1998	Magnin et al.	
000		US-5,739,135	04-14-1998	Biller et al.	
3333		US-5,760,246		Biller et al.	
		US-5,786,361	07-28-1998	Muller et al.	
8	A41*	US-5,789,197		Wetterau, II et al.	
0000		US-5,811,429		Connell et al.	
2000		US-5,827,875		Dickson, Jr. et al.	
		US-5,883,109	03-16-1999		
-		US-5,885,983	03-23-1999		
/ 1811		US-5,952,498	09-14-1999	Lenfers et al.	
		US-5,990,110	11-23-1999	Firestone	

Examiner /Kevin Weddington/	Date Considered	10/08/2009
-----------------------------	--------------------	------------

Initials							1					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many she ets as necess ary) Einst Named Inventor Daniel J. Rader An Unit 1614 Examiner Name Not Yet Assigned Not Yet Assigned Allowey Docket Number AGP-002 Allowey	Subs	titute for f	orm 1449/PTO				<u> </u>		,			
STATEMENT BY APPLICANT							Appli	cation Number	+			
Ast Unit 1614	IN	FOR	MATION	I DIS	SCLOSU	RE	Filing	Data	Septembe	r 5,	2006	
Art Unit 1614 Not Yet Assigned Not Yet Assigned Not Yet Assigned Artimory Docket Number AGP-002	S	ΓΑΤΕ	MENT E	BY A	PPLICA	NT	First	Named Inventor	Daniel J. F	Rade	er	
Sheet 2							Art Ur	nit	1614			
Sheet 2		(U	se as many she	ets as r	necess ary)		Exam	iner Name	Not Yet As	ssia	ned	
Mash US-6,034,115	Sheet		2	of			-		······			
A49" US-6,057,339 05-02-2000 Gregg A50" US-6,066,650 05-23-2000 Gregg et al. A51" US-6,066,650 05-23-2000 Gregg et al. A52" US-6,114,341 09-05-2000 Muller et al. A53" US-6,245,775 05-12-2001 Muller et al. A54" US-6,265,431 07-24-2001 Muller et al. A55" US-6,2733 10-02-2001 Muller et al. A55" US-6,297,233 10-02-2001 Site at al. A56" US-6,344,450 02-05-2002 Bisacchi et al. A56" US-6,492,365 12-10-2002 Wetterau, II et al. A58" US-6,492,365 12-10-2002 Wetterau, II et al. A59" US-6,492,365 12-10-2002 Wetterau, II et al. A69" US-6,602,21-A1 09-16-2003 Rob1 A60" US-6,602,21-A1 09-16-2003 Rob1 A61" US-6,627,936 09/20/2003 Rob1 A62" US-6,74,236 09/20/2003 Rob1 A63" US-6,74,236 09/20/2003 Rob1 A64" US-6,617,436 09/20/2003 Rob1 A65" US-6,868,862-A1 01-25-2005 Hamann et al. A66" US-6,868,862-A1 01-25-2005 Hamann et al. A66" US-6,868,862-A1 01-25-2005 Hamann et al. A68" US-6,916,809-A1 07-12-2005 Cheng et al. A69" US-6,916,809-A1 07-12-2005 Cheng et al. A71" US-6,979,809-A1 07-12-2005 Cheng et al. A72" US-7,053,980-A1 07-12-2005 Cheng et al. A73" US-7,053,980-A1 07-12-2005 Cheng et al. WW A72" US-7,053,980-A1 07-12-2005 Cheng et al. A73" US-7,056,986-A1 07-12-2005 Cheng et al. B18 EP-0779279 06-18-1997 Bayer Ag Sayor Ag		1		<u>, </u>			<u> </u>					
A50" US-6,066,650 05-23-2000 Bitter et at	/N.VV./	1,						al.				
A51" US-6,066,653 OS-23-2000 Gregg et al.	-											
A52' US-6,114,341												
A531 US-6,245,775 O6-12-2001 Multler et al.	-											
A551 US-6,265,431	-									ļ —		
A55' US-6,297,233												
A57' US-6,479,503-A1 11-12-2002 Wuller et al.		A55*	US-6,297,23	3					1			
A58' US-6,492,366												
A59* US-6,498,156-A1 12-24-2002 Glornbik et al.												—
A60' US-6,620,821-A1							erau,	n et di. it al		-		
A61* US-6;720,351-A1	_							it ai.		-		
A62* US-6,774,236	_									_		
A64* US-6,812,345-A1					04-13-200	04 Berti	inato	et al.				
A65° US-6,846,836-A1												
A66* US-6,858,622-A1 02-22-2005 Muller et al. A67* US-6,875,782-A1 04-05-2005 Cheng et al. A68* US-6,916,809-A1 07-12-2005 Cheng et al. A69* US-6,916,813-A1 07-12-2005 Atwal et al. A70* US-6,949,572-A1 09-27-2005 Bertinato et al. A71* US-6,949,572-A1 12-27-2005 Bertinato et al. A71* US-6,949,572-A1 12-27-2005 Bertinato et al. A71* US-6,949,572-A1 12-27-2005 Bertinato et al. A71* US-7,053,080-A1 05-30-2006 Davis et al. W.W. A72* US-7,056,906-A1 06-06-2006 Strony FOREIGN PATENT DOCUMENTS Foreign Patent Document Courtry Code*, Number*-Kind Code* (ff Known) MM-DO-YYYY Applicant of Cited Document Courtry Code*, Number*-Kind Code* (ff Known) MM-DO-YYYY Applicant of Cited Document Pages, Columns, Lines, When Relevant Passages of Relevent Figures Appear Year Pages, Columns, Lines, When Relevant Passages of Relevent Figures Appear Year Pages, Columns, Lines, When Relevant Passages of Relevent Figures Appear Year Pages, Columns, Lines, When Relevant Passages of Relevent Figures Appear Year Pages, Columns, Lines, When Relevant Passages of Relevent Figures Appear Year Pages, Columns, Lines, When Relevant Passages of Relevent Figures Appear Year Pages, Columns, Lines, When Relevant Passages of Relevent Figures Appear Year Pages, Columns, Lines, When Relevant Passages of Relevent Figures Appear Year Pages, Columns, Lines, When Relevant Passages Year Pag												
A68* US-6,875,782-A1										<u> </u>		
A68* US-6,916,809-A1 07-12-2005 Chen et al. A69* US-6,916,813-A1 07-12-2005 Afwal et al. A70* US-6,949,572-A1 09-27-2005 Bertinato et al. A71* US-6,979,692-A1 12-27-2005 Bertinato et al. A72* US-7,053,080-A1 05-30-2006 Davis et al. WW-WA73* US-7,056,906-A1 06-06-2006 Strony FOREIGN PATENT DOCUMENTS Foreign Patent Document Country Code* of known MM-DD-YYYY MPD-YYYY MPD-YYYYY MPD-YYYYYYY MPD-YYYYY MPD-YYYYYY MPD-YYYYY MPD-YYYYY MPD-YYYYYY MPD-YYYYYY MPD-YYYYYYY MPD-YYYYYY MPD-YYYYYY MPD-YYYYY MPD-YYYYYY MPD-YYYYYY MPD-YYYYY MPD-YYYYYY MPD-YYYYYY MPD-YYYYY MPD-YYYYYYY MPD-YYYYY MPD-YYYYYY MPD-YYYYYYYYY MPD-YYYYYYYY MPD-YYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYYY												
A69* US-6,916,813-A1 07-12-2005 Atwal et al.	-											
A70* US-6,949,572-A1	 											
A72* US-7,053,080-A1 05-30-2006 Davis et al.	V				09-27-200	05 Berti	inato	et al.				
Name of Patentee or Application Date Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear Name of Patentee or Applicant of Cited Document Publication Date Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages of Relevant Passages	*											
FOREIGN PATENT DOCUMENTS Foreign Patent Document Foreign Patent Document Cite Initials* No.** Country Code*-Number*-Kind Code* (# known) Date MM-DD-YYYY Pages, Columns, Lines, Where Relevant Passages of Relevent Figures Appear MM-DD-YYYY MM-DD-YYY MM-DD-YYYY MM-DD-YYYY MM-DD-YYYY MM-DD-YYYY MM-DD-YYYY MM-DD-YYYY MM-DD-	-/K-A/							<u>d. </u>				
Foreign Patent Document Publication Date Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages of Ralevent Figuras Appear The Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages of Ralevent Figuras Appear The Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages of Ralevent Figuras Appear The Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages of Ralevent Figuras Appear The Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages of Ralevent Figuras Appear The Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages of Ralevent Figuras Appear The Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages of Ralevent Figuras Appear The Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages of Ralevent Figuras Appear The Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages of Ralevent Figuras Appear The Name of Patentee or Applicant of Cited Document Pages of Ralevent Figuras Appear The Name of Pages, Columns, Lines, Where Relevant Passages of Ralevent Figuras Appear The Name of Pages of Pages, Columns, Lines, Where Relevant Passages of Ralevent Figuras Appear The Name of Pages of Pages, Columns, Lines, Where Relevant Pages of Ralevent Figuras Appear The Name of Pages of Pages, Columns, Lines, Where Relevant Passages of Ralevent Figuras Appear The Name of Pages of Ralevent Figuras The Name of Pages of Ralevent Figuras Appear The Name of Pages of Ralevent Figuras The Na	/1/244	•/[A/3*	US-7,056,90	6-A1	106-06-200	00 500	ny				 	
Foreign Patent Document Publication Date Name of Patentee or Applicant of Cited Document Pages, Columns, Lines, Where Relevant Passages of Ralevant					FOREIG	GN PATI	ENT (OCUMENTS				
Examiner No. Country Coda³-Number⁴-Kind Coda³ (# known) Name Palante of Cited Document Memory Palante of Cited Document No.			Foreign	Patent D					-11		Pages, Columns, Lines,	
RP-0142146											Where Relevant Passages	
B2 EP-0221025 05-06-1987 Sandoz Ag et al. B3 EP-0325130 07-26-1989 Bayer Ag Name					nd Coda (# Kriowii)			1		_ `	or reality and reposit	-
B3 EP-0325130 07-26-1989 Bayer Ag N B4 EP-0705831 04-10-1996 Bayer Ag N B5 EP-0779276 06-18-1997 Bayer Ag N B6 EP-0779279 06-18-1997 Bayer Ag N B7 EP-0799828 10-08-1997 Bayer Ag N B8 EP-0802198 10-22-1997 Bayer Ag N B9 EP-1 181 954 A 02-27-2002 Pfizer B10 EP-1099442 05-16-2001 Pfizer Prod Inc B11 CA-2091102 09-07-1993 Squibb & Sons Inc B12 GB-2205837 12-21-1988 Squibb & Sons Inc B13 FR-2596393 10-02-1987 Sanofi Sa N B14 AU-727895 07-23-1998 Bristol Myers Squibb Co B15 CA-2291471 06-04-2000 Pfizer Prod Inc B16 CA-2325201 05-10-2001 Pfizer Prod Inc B17 DE-19951022 04-26-2001 Bayer Ag N B18 JP-2002-220345 08-09-2002 Sumitomo Pharma N Examiner /Keyin Weddington/ Date 10/08/2009	/11.44.	+										┢
B4 EP-0705831 04-10-1996 Bayer Ag N	-								1.	_		╁
B5 EP-0779276 06-18-1997 Bayer Ag N B6 EP-0779279 06-18-1997 Bayer Ag N B7 EP-0799828 10-08-1997 Bayer Ag N B8 EP-0802198 10-22-1997 Bayer Ag N B9 EP-1 181 954 A 02-27-2002 Pfizer Pfizer Prod Inc Pfizer Prod Inc Pfizer Prod Inc Pfizer Prod Inc Pfizer Pfizer Prod Inc Pfizer Pfizer							-			+		Ť
B6 EP-0779279 06-18-1997 Bayer Ag No.										\dashv		1
B7 EP-0799828 10-08-1997 Bayer Ag N		_				-			 	\dashv		1
B8 EP-0802198 10-22-1997 Bayer Ag No.										+		Ť
B9 EP-1 181 954 A 02-27-2002 Pfizer B10 EP-1099442 05-16-2001 Pfizer Prod Inc B11 CA-2091102 09-07-1993 Squibb & Sons Inc B12 GB-2205837 12-21-1988 Squibb & Sons Inc B13 FR-2596393 10-02-1987 Sanofi Sa National States National Sta							-			\dashv		1
B10 EP-1099442 05-16-2001 Pfizer Prod Inc B11 CA-2091102 09-07-1993 Squibb & Sons Inc B12 GB-2205837 12-21-1988 Squibb & Sons Inc B13 FR-2596393 10-02-1987 Sanofi Sa Variable Sanofi Sa Variable Squibb Co B14 AU-727895 07-23-1998 Bristol Myers Squibb Co B15 CA-2291471 06-04-2000 Pfizer Prod Inc B16 CA-2325201 05-10-2001 Pfizer Prod Inc B17 DE-19951022 04-26-2001 Bayer Ag Variable Sanofi Sa Variable	- 00								· · · · · · · · · · · · · · · · · · ·	+		╁
B11 CA-2091102 09-07-1993 Squibb & Sons Inc B12 GB-2205837 12-21-1988 Squibb & Sons Inc B13 FR-2596393 10-02-1987 Sanofi Sa Variable Sanofi Sa Variab										1		1
B12 GB-2205837 12-21-1988 Squibb & Sons Inc									Inc	\dashv		1
B13 FR-2596393 10-02-1987 Sanofi Sa V	80000									\dashv		1
B14 AU-727895 07-23-1998 Bristof Myers Squibb Co										\neg		1
B15 CA-2291471 06-04-2000 Pfizer Prod Inc									quibb Co			
B16 CA-2325201 05-10-2001 Pfizer Prod Inc												
Kevin Weddington	V		CA-2325201									
Examiner /Keyin Weddington/ Date 10/08/2009	IL VAI									\perp		V
Examiner /Kevin Weddington/ Date 10/08/2009 Considered	111.44	.∕∫B18	JP-2002-220	0345		[08-09-2	002	Sumitomo Pha	ma			V
Signature Considered	Examine	er	Kevin Wa	ddina	ton/					1()/08/2009	
			LIVOAIII AAC	wairiy	1011/			С	onsidered			

Subs	titute for t	form 1449/PTO						Complete if Kno	wn	
						Appl	cation Number	10/591,923-0	Conf. #5393	
l in	FOR	MATION	I DI	SCLOSU	RE	Filing Dete September 5, 2006		, 2006		
	STATEMENT BY APPLICANT					First	Nemed Inventor	Daniel J. Rad	der	
•	.,		• • •			Art U	nit	1614		
	(U	se as many she	ets as	necess ary)	4	Exan	niner Name	Not Yet Assi	aned	
<u> </u>		3	of	5		AHon	nev Docket Number	AGP-002	9	
Sheet	,	<u> </u>	OI	3		Allon	ney Docket Number	AGF-002		
/K.₩.	B19	WO-00/0387	25		07-06-20	000	Searle & Co et a	ıl.		
8	B20	WO-01/0086	79		02-08-20	001	Verkade Hendril	k Jan		
	B21	WO-04/0285	44		04-08-20	004	Novo Nordisk A	'S		
	B22	WO-04/1103	68		12-23-20	004	Merck & Co., Inc	C		
	B23	WO-04/1103	375		12-23-20	004	Merkc & Co., Inc	C		
	B24	WO-05/0002			01-06-20	005	Merck & Co., Inc	Э.		
9900X	_	WO-05/0513			11-25-20	004	Yamanouchi Ph	armaceutical		V
		WO-05/0727			08-11-20	005	Japan Tobacco	Inc.		
3		WO-05/0846	• • • • • • • • • • • • • • • • • • • •				Abeille Pharmad			
	B28	WO-05/0948					Max-Planck Ges			
8	B29	WO-05/0971	31				Janssen Pharm			
8		WO-06/0466					Japan Tobacco			V
	B31	WO-06/0627					Reliant Pharma			
	B32	WO-06/0631					Sytera, Inc.	,		
	B33	WO-06/1086					Proteosys AG		-	
	B34	WO-06/1112					Merck Patent G	MBH		
	B35	WO-07/0478					Aegerion Pharm			
	B36	WO-05/0872			09-22-20	005	Rader			
	B37	WO-86/0034					Sandoz Ag			
90000	B38	WO-86/0070				_	Sandoz Ag et al	•		
-		WO-96/0262					Squibb Bristol M			
***************************************	B40	WO-96/0406					Pfizer et al.			
	B41	WO-97/0411	11				Pfizer et al.			
-	B42	WO-98/0030			01-29-19	998	Squibb Bristol M	lyers Co		
8	B43	WO-98/0031	174				Squibb Bristol M	lyers Co		
	B44	WO-98/0235			06-04-1	998	Pfizer et al.			
000	B45	WO-98/0279	79		07-02-1	998	Squibb Bristol M	lyers Co		
900	B46	WO-98/0312	225				Squibb Bristol M			
11/	B47	WO-98/0313	866_		07-23-1	998	Squibb Bristol M	lyers Co		
W	B48	WO-98/0313	367		07-23-19	998				
0412	, B49	WO-98/0500)28		11-12-19	998	Squibb Bristol M	lyers Co		
/K.V	₩B50	WO-07/0477	724		04-26-20	007	Wisler			

*EXAMINER: Initial if reference considered, whether or not citetion is in conformance with MPEP 609. Oraw line through citetion if not in conformance end not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those epptication(s) which ere merked with en single esterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that epptication was filed efter June 30, 2003 or is eveileble in the IFW. \(^1\) Applicant's unique citetion designation number (optional). \(^2\) See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \(^3\) Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\) For Jepanese patent documents, the indication of the yeer of the reign of the Emperor must precede the serial number of the patent document. \(^5\) Kind of document by the eppropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^6\) Applicant is to place a check mark here if English lenguage Translation is etteched.

Examiner	/Kevin Weddington/	Date	10/08/2009
Signature	// Com woodington	Considered	10/00/2000

Substitu	ite for form 1449/PT	·o		Complete if Known		
Gabania	10 10, 10, 11, 14, 10, 11			Application Number	10/591,923-Conf. #5393	
INF	INFORMATION DISCLOSURE			Filing Date	September 5, 2006	
ST	ATEMENT	BY AF	PPLICANT	First Named Inventor	Daniel J. Rader	
• • • • • • • • • • • • • • • • • • • •				Art Unit	1614	
	(Use as many	she ets as ne	cess ary)	Examiner Name	Not Yet Assigned	
Sheet	4	of	5	Attorney Docket Number	AGP-002	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journ al, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
K.W./	C1	Atzel, A., et al., "Mechanism of Microsomal Triglyceride Transfer Protein Catalyzed Lipid Transport", Biochemistry (1993), 32, 10444-10450.	
00000000000	C2	Bakillah A. et al., "Decreased Secretion of ApoB follows inhibition of ApoB-MTP Binding by a Novel Antagonist", Biochemistry (Mosc), (2000) 39(16):4892-4899.	
2000	СЗ	Barclay, "Hyperlipidemia", NMT Briefs, 2003.	
00000000	C4	Bayes, M., et al., "Gateways to Clinical Trials", Methods and Findings in Experimental and Clinical Pharmacology, 24(1):2002, 37-55.	
	C5	Bays et al., "Pharmacotherapy for Dyslipidaemia - Current Therapies and Future Agents", Expert Opin Phamacother, 2003 Nov;4(11):1901-38.	
X0000000	C6	Biller et al., "Isoprenoid (Phosphinylmethyl) Phosphonates as Inhibitors of Squalene synthetase", J. Med. Chem., 31 (10):1988, 1869-71.	
	C7	Bruckert, "New Lipid-Modifying Therapies", Expert Opin. Investig. Drugs, (2003)12(3):325-35.	
8	C8	Capson, T.L., (Ph.D. Dissertation, June, 1987, Dept. Med. Chem. U. of Utah, Abstract).	
CO000000000000000000000000000000000000	C9	Chang et al., "Microsomal Triglycende Transfer Protein (MTP) Inhibitors: Discovery of Clinically Active Inhibitors Using High-Throughput Screening and Parallel Synthesis Paradigms", Current Opinion in Drug Discovery & Development, (2002) 5(4):562-70.	
	C10	Corey and Volante, J. Am. Chem. Soc., (1976) 98:1291-93.	
0000000000	C11	de Montellano et al., "Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues", J. Med. Chem., (1977) 20:243-49.	
	C12	Earl et al., "Ezetimibe", Nature Reviews, 2003, 2:97-98.	
000000000	C13	Evans M. et al. "Medical Lipid-Regulating Therapy: Current Evidence, Ongoing Trials and Future Developments", Drugs: 2004; 64 (11): pp. 1181-1196	
000000000000000000000000000000000000000	C14	Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. National Cholesterol Education Program: Adult Treatment Panell III Report. Publication number 01-3095, I-1-IX-11. 2001. Bethesda, MD, National Heart, Lung, and Blood Institute.	
	C15	Farrell., "Drugs and Steatohepatitis", Semin Liver Dis, (2002) 22(2):185-194.	
000000000000000000000000000000000000000	C16	Gagne, et al. "Efficacy and Safety of Ezetimibe Coadministered with Atorvastatin or Simvastatin in Patients With Homozygous Familial Hypercholesterolemia", Circulation, (2002) 105 (21):2469-75.	
8	C17	International Search Report for Application No. PCT/US05/07435 dated July 14, 2005 (7 pages).	
000000000	C18	International Search Report for Application No. PCT/US06/040637 dated June 12, 2007 (8 pages).	
000000000000000000000000000000000000000	C19	International Search Report for Application No. PCT/US06/040639 dated June 12, 2007 (9 pages).	
	C20	International Search Report for Application No. PCT/US06/040640 dated May 23, 2007 (9 pages).	
200000000	C21	International Search Report for Application No. PCT/US06/040953 dated March 3, 2007 (8 pages).	
20000000	C22	Jamil et al., "An inhibitor of the Microsomal Triglyceride Transfer Protein Inhibits apoB Secretion From HepG2 Cells", Proc Natl Acad Sci U S A, (1996) 93(21):11991-11995.	
V	C23	Kastelein J., "What Future for Combination Therapies", Int J. Clin Pract. Suppl. 2003 March; (134): pp. 45-50	
*	Ç24	Kirkpatrick et al, "Market indicators", Nature, 2003, 2:98.	
/K.W	C25	Liao et al., "Blocking Microsomal Triglyceride Transfer Protein Interferes with apoB Secretion	

Examiner	/Kevin Weddington/	Date	10/08/2009
Signature	/Neviii vveddingtori/	Considered	10/00/E000

Complete if Known Substitute for form 1449/PTO 10/591,923-Conf. #5393 **Application Number** INFORMATION DISCLOSURE Filing Dete September 5, 2006 STATEMENT BY APPLICANT First Nemed Inventor Daniel J. Rader Art Unit 1614 (Use as many she ets as necessary) Examiner Name Not Yet Assigned 5 Attorney Docket Number AGP-002 Sheet of

/K.W./		Without Causing Retention or Stress in the ER", Journal of Lipid Research, (2003) 44(5):978.	
9	C26	McClard et al., J.A.C.S., (1987) 109:5544.	
9990000000000	C27	Ritter et al., "Heterocyclic Ring Scaffolds as Small-Molecule Cholesterol Absorption Inhibitors", Org. Biomol. Chem., 2005, 3:3514-3523.	
	C28	Robl et al, "A Novel Series of Highly Potent Benzimidazole-Based Microsomal Triglyceride Transfer Protein Inhibitors", Journal of Medicinal Chemistry, 2001, 44(6):851-856.	
200000000	C29	Shiomi et al, "MTP Inhibitor Decreases Plasma Cholesterol Levels in LDL Receptor-Deficient WHHL Rabbits by Lowering the VLDL Secretion", Euro. Journal of Pharma. 2001, 431:127-131.	
00000000	C30	Sorbera, L.A., et al., Implitapide "Hypolipidemic Treatment of Atherosclerosis MTP Inhibitor ApoB Secretion Inhibitor", Drugs of the Future, (2000) 25(11):1138-1144.	
000000	C31	Subhop et al., "Cholesterol Absorption Inhibitors For the Treatment of Hypercholesterolaemia", Drugs, 2002, 62(16):2333-2347.	
8844440000	C32	Thomas et al., "Alleviation of MTP Inhibitor-Induced Hepatic Steatosis in Hyperlipidemic fa/fa Rats by Fenofibrate", Dept. of Metabolic Diseases and Dept. of Chemical Research, Boehringer Ingelheim Pharma GmbH & Co. KG.	
000000000000000000000000000000000000000	C33	Wetterau et al., "An MTP Inhibitor that Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits", Science, (1998) 282(5389):751-754.	
V	C34	Wetterau et al., "Microsomal Triglyceride Transfer Protein", Biochimica Biophysica Acta, (1997) 1345(2):136-150.	
/K.W.	/C35	Wierzbicki A.S., "New Lipid-Lowering Agents", Expert Opinion on Emerging Drugs, Ashley Publications, GB, 8 (2):2003, 365-376.	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformence with MPEP 609. Draw line through citetion if not in conformence end not considered. Include copy of this form with next communication to epplicant.

LIBC/3095947v1

Examiner		Date 10/08/2009
	// accin this adding atom /	1 10/00/2003
Signature	/Kevin Weddinaton/	Considered
Signature	///OVIII V COOMIQION	

¹Applicant's unique citetion designation number (optional). ²Applicant is to place a check mark here if English lenguege Trensletion is etteched.